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a  b  s  t  r  a  c  t
Two chronic  dietary  studies,  conducted  years  apart,  with  ammonium  perﬂuorooctanoate
(APFO)  in  Sprague  Dawley  rats  have  been  previously  reported.  Although  both  included  male
300 ppm  dietary  dose  groups,  only  the  later study,  conducted  in 1990–1992  by Biegel et al.,
reported  an increase  in proliferative  lesions  (hyperplasia  and  adenoma)  of  the  acinar  pan-
creas. An  assessment  of  the  signiﬁcance  of the  differences  between  both  studies  requires
careful  consideration  of:  the  diagnostic  criteria  for proliferative  acinar  cell lesions  of the  rat
pancreas (for  example,  the  diagnosis  of  pancreatic  acinar  cell  hyperplasia  versus  adenoma
is based  on the  two-dimensional  size  of  the  lesion  rather  than  distinct  morphological  dif-
ferences);  the  basis  for those  criteria  in  light  of their  relevance  to biological  behavior;  and
the  potential  diagnostic  variability  between  individual  pathologists  for difﬁcult-to-classify
lesions.  A pathology  peer  review  of  male  exocrine  pancreatic  tissues  from  the  earlier  study,
conducted  in 1981–1983  by Butenhoff  et al., was  undertaken.  This  review  identiﬁed  an
increase  in  acinar  cell  hyperplasia  but  not  adenoma  or carcinoma  in  the  earlier  study.
Both studies  observed  a proliferative  response  in the  acinar  pancreas  which  was more
pronounced  in  the  study  by Biegel  et  al.  Deﬁnitive  reasons  for  the  greater  incidence  of  pro-
liferative lesions  in  the later  study were  not  identiﬁed,  but  some  possible  explanations  are
presented  herein.  The  relevance  of  this  ﬁnding  to  human  risk  assessment,  in  the  face  of
differences  in  the  biological  behavior  of  human  and  rat  pancreatic  proliferative  lesions  and
the proposed  mechanism  of  formation  of these  lesions,  are questionable.
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1. Introduction
The ammonium salt of perﬂuorooctanoic acid (APFO,
CASRN 3825-26-1) has been used commercially as a
surface-active agent in the production of various ﬂuo-
ropolymers. APFO has been demonstrated to activate the
xenosensor nuclear receptor NR1C1 (the peroxisome pro-
liferator  activated receptor , or PPAR ) and is therefore
a member of a class of compounds known as peroxisome
proliferators.
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The extensive toxicology database for this chemical has
been  reviewed [1,2], and includes two chronic (2-year)
dietary studies in Sprague Dawley rats conducted several
years  apart in different laboratories [3,4]. Results of a study
conducted in 1981–1983 were reported by Butenhoff et al.
[4],  and those of the other study, conducted in 1990–1992,
were reported by Biegel et al. [3]. The Biegel et al. study was
undertaken to investigate the modes of action of selected
effects of APFO observed in the study reported by Butenhoff
et  al., with emphasis on changes in response over a chronic
dosing period. Although there were some differences in the
study  protocols between the two studies, common to both
studies  was a group of male Sprague Dawley rats fed AFPO
at  a dietary concentration of 300 ppm (∼14 mg/kg-d) for
2  years. Results for the male groups at this concentration
were similar between the two studies for most endpoints
evaluated. However, one difference noted was the pres-
ence  of treatment-related increases in the incidences of
proliferative lesions (hyperplasia and adenoma) of pancre-
atic  acinar cells in the Biegel et al. study that were not
observed in the Butenhoff et al. study. The presence of an
APFO  treatment-related increase in pancreatic acinar cell
hyperplasia and adenoma in the Biegel et al. study was con-
sistent  with the observed pancreatic effects of a number of
known  peroxisome proliferators [5].
To better understand the apparent difference between
the two studies with respect to pancreatic acinar cell
lesions, pancreatic tissues from the Butenhoff et al. study,
which  reported no effect on the exocrine pancreas, were
re-evaluated microscopically. This peer review evaluated
proliferative acinar cell lesions of the pancreas using the
currently recommended diagnostic criteria for pancreatic
acinar cell lesions in rodents [6], criteria which became
available in the interim between the two studies and were
used  in the evaluation of the Biegel et al. study. In addi-
tion,  it involved a pathologist common to both studies in
order  to enhance the diagnostic consistency between the
two  studies.
This paper uses this rigorous scientiﬁc approach to
examine the collection of pancreatic tissues from two
published studies to look for commonalities and differ-
ences using currently recommended pathology diagnostic
criteria in a manner that neutralizes potential diagnostic
variability between studies. In doing so, it was concluded
that the pancreas is indeed a target for APFO and that
the  responses in the two studies reﬂect the spectrum of
changes  from normal to adenoma with those in one study
being  more advanced (both in incidence and in terms of
lesion  size). Thus, there is no need to separate the two stud-
ies  as if the ﬁndings in this tissue are contradictory, as has
been  largely done to this point in review literature. This
report  provides the results of that microscopic review and
discusses  the signiﬁcance of the differences seen between
the  two chronic studies in rats with APFO with respect to
proliferative lesions of pancreatic acinar cells.
2. MethodsTwo chronic dietary toxicity studies were performed
with APFO in Sprague Dawley rats: the study reported
by Butenhoff et al. (hereafter referred to as Study 1) was Reports 1 (2014) 85–91
conducted at 3M Company (Riker Laboratories, St. Paul,
MN,  April 1981–May 1983), and the study reported by
Biegel  et al. (hereafter referred to as Study 2) was conducted
at  DuPont (Haskell Laboratory, Newark, DE, December
1990–December 1992). These studies have been previously
reported [3,4].
In  Study 1, male and female rats were fed 0, 30 and
300 ppm APFO and sacriﬁced at 2 years (terminal sacri-
ﬁce). This study also included a 1-year interim sacriﬁce
for the 0 and 300 ppm groups only. The pathology results
as  reported by the study pathologist for Study 1 were not
peer  reviewed at the time although selected slides were
subjectively reviewed at a later date [4].
Study 2 was conducted in male rats only and included a
group  fed 300 ppm APFO and two 0 ppm control groups: an
ad  libitum control group and a control group pair-fed to the
APFO-fed  group. There were multiple interim sacriﬁces in
this  mechanistic study, and the results from those evalua-
tions  are reported by Biegel et al. [3]. The current report will
compare  the results of the re-evaluation of Study 1 with the
published  results of the core study of Study 2, where rats
were  sacriﬁced following up to 2-years dietary exposure
to  APFO. The pathology results as reported by the study
pathologist for Study 2 were previously peer reviewed by
a  second pathologist.
For  the current report, a limited pathology peer review
of  Study 1 was  conducted on formalin-ﬁxed, parafﬁn-
embedded, hematoxylin & eosin stained sections of all
available pancreatic tissues from male rats (two slides
from the 300 ppm terminal sacriﬁce group were deemed to
contain  insufﬁcient pancreas tissues hence they were not
included  in the review). The review pathologist for this re-
evaluation  (SRF) had served as the primary pathologist on
Study  2, thus providing one reviewer common to both stud-
ies.  In addition, any differences in diagnoses of proliferative
acinar cell lesions between the study and review patholo-
gists  of Study 1 were also examined by a second reviewing
pathologist (JMCR). The updated results reported herein
for  Study 1 reﬂect agreement between the two  review-
ing pathologist (the study pathologist for Study 1 was  not
available to participate in this review). Since the pathology
results from Study 2 had already undergone a pathology
peer review, further evaluation of pancreatic tissue from
that  study was  not conducted, and the results of that study
as  given herein are as originally reported by Biegel et al. [3].
Also,  since Study 2 did not include females, female pancre-
atic  tissue from Study 1 was not included in the current
review. Proliferative lesions of the exocrine pancreas were
not  reported in female rats in Study 1 [4].
Criteria used for the diagnosis of pancreatic acinar
hyperplasia, adenoma and carcinoma were those recom-
mended by Hansen et al. [6]. Namely, acinar proliferative
lesions diagnosed as hyperplasia were well-delineated,
generally oval lesions composed of closely packed acinar
cells  with slightly enlarged nuclei arranged in an elon-
gated acinar pattern. Mitoses and apoptotic cells were
occasionally seen. The diagnosis of adenoma was  ascribed
to  lesions that appeared similar morphologically to hyper-
plastic  lesions, yet were greater than 5 mm in diameter.
The diagnosis of carcinoma was  assigned to proliferations
that had morphologic indicators of malignancy: namely,
J.M. Caverly Rae et al. / Toxicology Reports 1 (2014) 85–91 87
Table 1
Comparison of incidence of pancreatic acinar cell hyperplastic and neoplastic observations between the chronic dietary studies (at 2 years unless otherwise
indicated)  in rats fed ammonium perﬂuorooctanoate (APFO) as reported by Butenhoff et al. [4], pre-and post-review, and Biegel et al. [3].
Butenhoff et al. [4] (Study 1) Biegel et al. [3] (Study 2)
Control 30 ppm APFO 300 ppm APFO Control Pair-fed control 300 ppm APFO
Hyperplasia (H)
Initial  review 0/46 (0) 2/46 (4) 2/49 (4) 14/80 (18)a 8/79 (10) 30/76 (39)#
Post-reviewb 3/46 (7) 1/46 (2) 10/47c (21)*
Adenoma (A)
Initial  review 0/46 (0) 0/46 (0) 0/49 (0) 0/80 (0) 1/79 (1) 7/76 (9)#
Post-review 0/46 (0) 0/46 (0) 0/47c (0)
Carcinoma  (C)
Initial  review 0/46 (0) 0/46 (0) 0/49 (0) 0/80 (0) 0/79 (0) 1/76 (1)
Post-review 0/46 (0) 0/46 (0) 1/47c (2)
Combined  (H + A + C)
Initial review 0/46 (0) 2/46 (4) 2/49 (4) 14/80 (18) 9/79 (11) 38/76 (50)#
Post-review 3/46 (7) 1/46 (2) 11/47c (23)*
a Rats with ﬁnding/rats examined (%).
b Represents the consensus diagnosis following review post-study.
c During the pathology re-evaluation of Butenhoff et al. study, two  slides were deemed to contain insufﬁcient pancreas tissues hence they were not
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acinar  cell tumors, the conclusions of the peer review were
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ancluded  in the review.
# Signiﬁcantly different from pair-fed control group (p < 0.05).
* Positive by Cochran–Armitage trend test (p < 0.05).
reas of poor differentiation, ﬁbroplasia, necrosis, capsular
r  vascular invasion and/or high mitotic rate.
For both studies, incidences of acinar cell hyperpla-
ia and neoplasia in the treated and control groups were
ompared for statistical signiﬁcance as judged at P ≤ 0.05.
he  statistical analysis for the data from Study 2 was
eported by Biegel et al. [3]. For the data created by peer
eview of Study 1 as reported in this manuscript, the sta-
istical  analysis included the Fisher’s exact test and the
ochran–Armitage test for trend.
. Results
For most pancreases evaluated from Study 1, the
eviewing pathologists were in agreement with the study
athologist. Exceptions included several instances of pan-
reatic  acinar cell hyperplasia observed by the review
athologists that were not reported as part of the origi-
al  microscopic evaluation (Table 1; Fig. 1A and B). These
ccurred predominantly in the 300 ppm group but were
ig. 1. Pancreas from a control male rat (Study 1). (A) Low magniﬁcation of a well
igher  magniﬁcation of (A) at border of hyperplastic (H) and normal (N) regions. A
nd  branching of acinar units, increased mitoses (arrowhead), and areas of apoptalso  observed in control rats (Table 1). In addition, two
instances (2/15) of acinar cell hyperplasia were seen in the
300  ppm interim sacriﬁce group (not included in Table 1)
and  one lesion originally identiﬁed as acinar cell hyperpla-
sia  in a 30 ppm rat was considered to be a basophilic focus
of  cellular alteration. Further, one male rat in the 300 ppm
group  was considered to have an acinar cell carcinoma,
which was  not previously diagnosed (Fig. 2A and B); how-
ever,  the presence of this lesion is of uncertain relationship
to treatment given its single incidence. The spontaneous
incidence of acinar cell carcinoma is less than 1% in male
rats  of this strain [7–9].
Based  on the results of the peer review of the pancreases
in Study 1, the incidence of pancreatic acinar cell hyperpla-
sia  was  statistically signiﬁcantly elevated in the 300 ppm
group  as compared to controls. However, with respect toin  agreement with the original study report in that there
were  no statistically signiﬁcant or test substance-related
increases in acinar cell neoplasms (adenoma or carcinoma)
-circumscribed area of acinar cell hyperplasia (arrows). Bar = 500 m. (B)
reas of hyperplasia have crowding of acinar cell nuclei, some elongation
osis and dropout of acinar cells (arrow). Bar = 20 m.
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agniﬁca
cinar ceFig. 2. Pancreas from a male rat fed 300 ppm APFO (Study 1). (A) Low m
(c).  Bar = 500 m.  (B) Higher magniﬁcation of (A) showing neoplastic a
(arrowheads) and apoptosis (arrows). Bar = 50 m.
following chronic dietary exposure to 30 or 300 ppm APFO
in  Study 1.
4.  Discussion
Only two studies to date have assessed chronic dietary
exposure to APFO in rats. Although many of the endpoints
assessed in these studies were collaborative, one observa-
tion  that appeared to not be common to both studies was
the  ﬁnding of increased pancreatic acinar proliferations.
This apparent contradiction was addressed in this study via
a  rigorous scientiﬁc approach that examined the collection
of  pancreatic tissues from both studies to look for com-
monalities and differences using currently recommended
pathology diagnostic criteria in a manner that enhanced
the diagnostic consistency between the studies. In doing
so,  it was concluded that the pancreas is indeed a target for
APFO  and that the responses in the two studies reﬂect the
spectrum of changes from normal to adenoma with those
in  one study being more advanced (both in incidence and
in  terms of lesion size). Thus, there is no need to separate
the two studies as if the ﬁndings in this tissue are contra-
dictory, as has been largely done to this point in review
literature.
Based on the results of this review of pancreatic tis-
sue from the Butenhoff et al. [4] chronic study (Study 1)
conducted in rats with APFO, the test substance produced
an  increased incidence of pancreatic acinar cell hyperpla-
sia  in male rats fed 300 ppm in this study. This review did
not  identify pancreatic acinar cell adenomas in this study.
In  partial contrast to these results, Biegel et al. [3] (Study
2)  reported increased incidences of acinar cell hyperpla-
sia and adenoma in male rats fed 300 ppm (Fig. 3A–C). The
incidences of pancreatic acinar cell hyperplasia reported
by  Biegel et al. [3] were higher than those observed in this
peer  review of the study reported by Butenhoff et al. [4].
An  assessment of the signiﬁcance of the differences
between both studies requires consideration of the bio-
logical  behavior of pancreatic acinar cell hyperplasia and
neoplasia, recommended diagnostic criteria for prolifera-
tive  acinar cell lesions of the rat pancreas and the basis
for  those criteria, and the potential diagnostic variabil-
ity between individual pathologists for difﬁcult-to-classifytion of an acinar cell carcinoma partially encapsulated by ﬁbrous tissue
lls arranged in solid sheets or irregular tubules with frequent mitoses
lesions. Proliferative lesions of the acinar pancreas of the
rat  are thought to exist along a continuum of hyper-
plasia, adenoma, and carcinoma. However, the likelihood
of  progression or regression along that continuum is
unknown in most cases, and although acinar cell car-
cinomas are clearly distinguishable morphologically as
an  entity, typically there are no cytological features that
clearly distinguish hyperplasia from adenoma [6,10]. To
achieve  some uniformity in diagnoses across laboratories,
diagnostic criteria have been established to differentiate
acinar cell hyperplasia from adenoma, and the criterion
most commonly employed is the somewhat arbitrary fea-
ture  of two-dimensional size of the lesion [6,10]. Thus,
for  many acinar cell proliferations, the difference between
the  diagnoses of hyperplasia and adenoma reﬂects a dif-
ference  in the two-dimensional area of a random section
through the lesion rather than known differences in bio-
logical  potential.
Based  on these considerations, it is apparent that the
pancreatic effects in both chronic feeding studies in rats
with  APFO are qualitatively similar, as APFO produced
increased incidences of proliferative acinar cell lesions of
the  pancreas in both studies. The differences observed were
only  quantitative in nature, that is, more and larger focal
proliferative acinar cell lesions were produced in Study 2
as  compared to Study 1. Since size (partially dependent
on random two-dimensional sectioning through a three-
dimensional lesion) is the primary diagnostic criterion
distinguishing acinar cell hyperplasia from neoplasia in
rodents,  the tendency toward larger proliferative lesions
accounts for the ﬁnding of test-substance related adeno-
mas  in Study 2 but not in Study 1.
The reason for this quantitative discordance despite
use of the same rat strain and dietary concentration of
APFO  (300 ppm) in the two  studies is not known. How-
ever, there are a number of variables that could contribute
to  the differences observed. Hyperplasia was diagnosed
more commonly in the control rats in Study 2, implying a
higher  background incidence in those rats. Although both
studies  used CD Sprague Dawley rat stock from Charles
River Laboratories (sourced from different breeding facili-
ties),  these studies were conducted approximately 10 years
apart  and in different laboratories. It is expected that these
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Fig. 3. Pancreas from a male rat fed 300 ppm APFO (Study 2). (A) Low magniﬁcation of acinar cell hyperplasia (H) and acinar cell adenoma (A). Note that
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cinar  hyperplasia and adenoma, respectively, from (A). Note that the mo
o  the acinar cell hyperplasia present in Fig. 1B from a control rat (mitose
emporal and locational variables were associated with
ome  differences in animal husbandry, including diet, as
ell  as potential genetic drifts within the rat strain over
he  interim between the conduct of the two studies. Dur-
ng  this time, Charles River was experiencing a decrease
n  longevity in its breeding stock that elicited a change in
ts  breeding program [4]. However, of all possible factors,
n  undetermined difference in the diets is the most likely
actor  inﬂuencing the different incidences of proliferative
cinar cell lesions. Various forms of dietary manipulation,
ncluding feeding raw soy diets or diets deﬁcient in choline,
re  known to moderate the incidences of acinar cell hyper-
lasia  and neoplasia in the pancreas of rodents [11,12]. For
nstance,  the incidences of acinar cell hyperplasia and ade-
oma  were increased ﬁve-fold in control male F344 rats
iven  corn oil by gavage compared to rats not gavaged [10].
ample  source, purity and average daily APFO consump-
ion by 300 ppm group males in both studies were quite
imilar (14.2 mg/kg in Study 1 and 13.6 mg/kg in Study
).  However, the studies used different base diets. Certi-
ed  Purina Laboratory Chow (Ralston Purina, Inc., St. Louis,
issouri) was used in Study 1 and Certiﬁed Rodent Diet
5002  (PMI Feeds, Inc.) was used in Study 2. Differences in
iet  composition between these two diets may  have inﬂu-
nced  the pancreatic acinar cell responses given the known
nﬂuence of dietary manipulation on proliferative acinar
ell  lesions in the rat. However, the precise dietary factors
hat  may  have been involved are not known. There may  be
ther  potential explanations for differences in outcomeslar except for their size. Bar = 500 m. (B and C) Higher magniﬁcation of
ic similarity of the hyperplasia and adenoma, and the similarity of both
wheads and apoptosis at arrows). Bars = 20 m.
between the two studies, but no conclusion can be reached
at  present.
APFO belongs to a class of compounds known as PPAR
agonists. The leading theory for the mechanism of induc-
tion  of pancreatic acinar cell proliferative lesions by APFO
and  other PPAR agonists in the rat is based, in a large part,
on  studies involving the potent PPAR agonist, WY14,643.
A  proposed mode of action is initiated by PPAR activa-
tion in the liver, which alters bile acid composition through
enhanced cholesterol/triglyceride excretion and/or causes
cholestasis thereby decreasing the total bile acid output
[3,13–15]. This change in the composition and output of
bile  triggers increased cholecystokinin (CCK) levels due
to  enhanced release of CCK from the intestinal mucosa
[16,17]. As CCK has been shown to be a growth factor for
rat  pancreatic acinar cells via direct binding to acinar CCK1
receptors, this sustained increase in CCK elicits pancreatic
acinar hyperplasia, eventually progressing from hyperpla-
sia  to neoplasia [3,18]. This mode of action is unlikely to
be  relevant to humans, as humans regulate exocrine pan-
creatic  secretion via a neuronal, cholinergic pathway (i.e.,
indirectly) rather than by direct binding of CCK to pancre-
atic  acinar cell receptors [19–21]. Human acinar cells do
not  have functional CCK receptors, nor are they responsive
to  physiological concentrations of CCK in vitro; whereas
CCK1 receptors are plentiful on rat acinar cells and rat
acinar cells are responsive to physiological concentrations
of CCK in vitro [22–26]. Further, CCK is a potent stimu-
lator of pancreatic enzyme secretion in the rat. This is in
xicology
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apparent contrast to humans in which in vivo studies with
a  CCK1R antagonist indicate that CCK is not an essential
intermediary of post-prandial pancreatic enzyme secretion
[24,26,27]. In considering the human relevance of acinar
cell  hyperplasia and neoplasia in the rodent, it is notewor-
thy  that the histological type of tumor seen in the rodent
is  distinctly different from tumors of the exocrine pan-
creas  most commonly observed in humans. While rodent
tumors typically display acinar differentiation, the major-
ity  of human pancreatic neoplasms are of the ductular
type [11,28]. True ductular neoplasms of the pancreas are
rare  in rats [29]. In addition, while rodent tumors typi-
cally  have no noticeable effects on the rodent’s morbidity
or  mortality, the majority of human pancreatic neoplasms
carry a dismal 5-year survival rate of 6% [30]. Mutation
causing activation of the proto-oncogene KRAS occurs in
>90%  of human pancreatic ductular adenocarcinomas, and
this  mutation is found in even the earliest precancerous
pancreatic lesions in humans [31,32]. The more advanced
neoplastic exocrine pancreatic lesions in humans acquire
additional mutations, largely in tumor suppressor genes
[31].  PFOA has not shown mutagenic or clastogenic activ-
ity  in a variety of standard assay systems [33], and is thus
unlikely to be a complete carcinogen. In addition, pan-
creatic acinar cell hyperplasia and neoplasia have been
produced in rats by a number of compounds which, like
APFO,  produce peroxisome proliferation in the liver. These
include  pharmaceuticals widely used in humans, such as
the  hypolipidemic agents, cloﬁbrate and nafenopin. There
is  no known association between these compounds and
tumors  of the exocrine pancreas in humans. Of particu-
lar  interest, cancer epidemiology of human populations
exposed to PFOA, including occupational exposure, has not
found  increased risk or incidence of pancreatic cancer to
be  associated with PFOA exposure [34–36]. Although the
mechanism leading to the formation of proliferative lesions
of  the acinar pancreas in rats is not well-understood, in the
context  of human health risk assessment, such lesions are
of  questionable relevance.
In  conclusion, microscopic lesions observed in the
exocrine pancreas in a chronic feeding study in rats with
APFO  were re-evaluated using current diagnostic criteria
and  involving a pathologist common to both studies. The
results  of that review were compared to those reported in a
second  study in the same strain of rat. These reviews were
conducted to clarify apparent differences between the two
studies  relative to compound-related proliferative lesions
of  the exocrine pancreas. The results of the two studies
were similar in that APFO produced proliferative lesions
of  pancreatic acinar cells in both studies at dietary concen-
trations of 300 ppm. In the ﬁrst study, treatment-related
changes were limited to increases in acinar cell hyperplasia.
In  the second study, increased incidences of both hyper-
plasia and adenoma of acinar cells were observed. Thus,
these  studies produced qualitatively similar responses in
the  pancreas, with the differences noted being largely
quantitative in nature, that is, higher overall incidences of
proliferative lesions and a tendency toward larger areas
of  proliferation in the second study compared to the
earlier study. Although the basis for the quantitative differ-
ence  observed is not known, since the difference between
[ Reports 1 (2014) 85–91
pancreatic acinar hyperplasia and adenoma in the rat is
based  primarily on the size of a random section through the
lesion,  and not necessarily biological potential, the results
of  the two studies are in reasonable concordance given the
experimental variables that exist between them. A num-
ber  of variables, especially diet, are known to modulate the
proliferative response of the acinar pancreas in rats and
are  likely operative in the differences in degree of response
seen  in the two  chronic studies with APFO. Despite these
differences, target organ effects on the pancreas, character-
ized  by focal proliferative lesions of pancreatic acinar cells,
were  common to both studies. The relevance of this ﬁnding
to  human risk assessment, in the face of differences in the
biological behavior of human and rat pancreatic prolifera-
tive  lesions and the proposed mechanism of formation of
these  lesions, is questionable.
Source  of funding
DuPont Company and 3M Company funded the studies
reported herein.
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